Abstract: An ophthalmic preparation of a tyrosine kinase inhibitor suitable for eye drop administration is prepared from the following active ingredients and adjuvants in parts by weight: active ingredient: 0.5-1.5 parts of tyrosine kinase inhibitor, wherein the content of the active ingredient in the ophthalmic preparation is 0.1-1 mg/mL; and pharmaceutically acceptable adjuvants: 200-300 parts of the surfactant, 0.5-7.0 parts of the tackifier, 10-800 parts of the solubilizer, with the balance being solvent. The ophthalmic preparation can effectively deliver the active ingredient to the fundus oculi to treat fundus angiogenesis diseases, with high absorption and utilization rate, small particle size and good stability, which are suitable for preparing sterile preparation by means of microporous filter membrane sterilization method and/or high-temperature sterilization method.

Abstract: A carrier or auxiliary material of an ophthalmic preparation, a preparation method therefor, and an application thereof, relating to the field of ophthalmic drug delivery. The carrier or auxiliary material of the ophthalmic preparation contains components such as a surfactant and an ionic polymer, and also contains a solvent. Or, the carrier or auxiliary material of the ophthalmic preparation contains components of low-polymerization-degree povidone and medium-polymerization-degree povidone, and also contains a solvent. Spherical nanobodies are formed in the solvent by the component contained in the carrier or auxiliary material of the ophthalmic preparation, have a particle size of 1-100 nm, and can be self-assembled to form spherical nanospheres having a particle size of 10-2000 nm. The administration carrier can wrap a drug through an anterior segment to efficiently deliver the drug to a posterior segment to play a therapeutic action.

Abstract: An ophthalmic formulation for preventing and treating cataracts contains an active substance for treating eye diseases and a pharmaceutically acceptable carrier or excipient. The active substance is oxidized cholesterol, including lanosterol or 25-hydroxycholesterol; the pharmaceutically acceptable carrier or excipient contains a surfactant, a tackifier, a cosolvent, and a solvent; the content of the oxidized cholesterol in the formulation is 0.01-5 mg/mL; and the mass ratio of the surfactant, the tackifier, the cosolvent, and the oxidized cholesterol is (1-300):(1-100):(100-3000):1, with the balance being the solvent. Upon eye drop administration, the formulation can cause the active substance to be selectively enriched in the lens of a laboratory animal to accurately exert the effect of treating cataracts. The active substance is not distributed in the aqueous humor and the vitreous body, thereby avoiding toxic and side effects on other eye tissue and the whole body.

Abstract: An ophthalmic preparation is effective for preventing and treating dry macular degeneration and retinal light damage. The preparation includes an active ingredient for treating an ocular disease and an ophthalmic preparation carrier or adjuvant. The active ingredient for treating the ocular disease is an adenylate-activated protein kinase activator and/or an anti-inflammatory active ingredient. The ophthalmic preparation carrier or adjuvant contains the following components: a surfactant, an ionic macromolecule, and a solvent. The ophthalmic preparation can be administered by eye drops for carrying (wrapping) the adenylate-activated protein kinase activator and/or the anti-inflammatory active ingredient through the anterior eye segment, and delivering same to a posterior eye segment for preventing and treating dry macular degeneration and retinal light damage.